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Abstract
Background: The chemokine receptors (CKRs), mainly CCR5 and CXCR4 function as major coreceptors in infections
caused by human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). Approximately 20 G
protein-coupled receptors (GPCRs) have been identified as minor coreceptors, alike CCR6 that we reported recently.
Since CKR-L3 is indentified as a natural isoform of CCR6, we attempted in this study to explore the coreceptor
function of CKR-L3.
Methods: NP-2 cells transduced with CD4-receptor (NP-2/CD4) normally remain resistant to HIV or SIV infection.
However, the introduction of functional coreceptors can make these cells susceptible to these viruses. NP-2/CD4/
CKR-L3 cells were produced to examine the coreceptor activity of CKR-L3. Likely, CCR6-isoform and the major
coreceptors, CCR5 and CXCR4 were also examined in parallel. Presence of viral antigen in infected NP-2/CD4/
coreceptor cells was detected by indirect immunofluorescence assay (IFA). The results were validated by detection
of syncytia, proviral DNA and by measuring reverse transcriptase (RT) activities.
Results: HIV-2MIR and SIVsmE660 were found to infect NP-2/CD4/CKR-L3 cells, indicative of the coreceptor function
of CKR-L3. Viral antigens appeared faster in NP-2/CD4/CKR-L3 cells than in NP-2/CD4/CCR6, indicating that CKR-L3 is
a more efficient coreceptor. Moreover, syncytia formation was more rapid and RT release evidenced earlier and at
higher levels with CKR-L3 than with CCR6. Sequence analysis in the C2-V3 envelope region of HIV-2MIR replicated
through CKR-L3 and CCR6 coreceptor showed two and three amino acid substitutions respectively, in the C2 region
compared to the CCR5-variant. The SIVsmE660-CKRL3 variant showed three amino acid substitutions in the V1
region, one change in the V2 and two changes in the C2 region. The SIVsmE660-CCR6 variant produced two
changes in the V1 region, and three in the C2 region.
Conclusions: Isoform CKR-L3 exhibited coreceptor activity for limited primary HIV and SIV isolates with better
efficiency than the parent CCR6-isoform. Amino acid substitutions in the envelope region of these viruses may
confer selective pressure towards CKR-L3-use. CKR-L3 with other minor coreceptors may contribute to HIV and
SIV pathogenesis including dissemination, trafficking and latency especially when major coreceptors become
compromised. However, further works will be required to determine its clinical significance in HIV and SIV infection.
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Background
Human immunodeficiency virus (HIV) and simian im-
munodeficiency virus (SIV) infect susceptible cells by the
interaction of the viral envelope (Env) glycoprotein gp120
with the CD4 receptor [1] and a suitable coreceptor, pref-
erably one of the two chemokine receptors (CKRs), CCR5
or CXCR4 [2]. Some HIV-1, HIV-2 and SIV strains and
isolates have the ability to use coreceptors independent of
CD4 to infect target cells both in vitro and in vivo [3-5].
The coreceptor tropism is defined based on the ability of
viruses to use particular coreceptors, hence dividing HIV
and SIV strains into three primary groups: R5 viruses that
use CCR5 as their coreceptor, X4 viruses that utilize
CXCR4 as their coreceptor and R5X4 or dual tropic vi-
ruses that can use either of the two coreceptors [6]. The
majority of viral strains initiate infection through the
CCR5 receptor [7], then subsequently change their core-
ceptor shifting to CXCR4, probably expand to more other
coreceptors [8]. The switching from R5 to X4 or multi-
tropism accelerates CD4+ T cell depletion and rapid dis-
ease progression in vivo [9]. Apart from the major two
coreceptors, more than 12 CKRs and several orphan G
protein-coupled receptors (GPCRs) have been identified
as coreceptors for different HIV and SIV strains [10,11].
Additional coreceptors using solely by SIV have also been
demonstrated in vivo in Sooty mangabey infections in the
CCR5-depleted condition [12]. Recently, we reported the
role of CCR6, a 374 amino acid polypeptide, as a func-
tional coreceptor for limited HIV and SIV isolates [13].
The open reading frame (ORF) of CCR6 carries a second
exon-frame that initiates translation from the second me-
thionine of the amino-terminal region (NTR) and encodes
a polypeptide of 369 amino acids [14]. This alternate ver-
sion of CCR6-isoform is known as CKR-L3 [15]. In this
study, we investigated the coreceptor activity of CKR-L3
in comparison to CCR6. We find coreceptor activity of
CKR-L3 to be stronger than that of CCR6 for the primary
isolates, HIV-2MIR and SIVsmE660.
Methods
Cells
The human glioma cell line NP-2 expresses neither CD4
nor coreceptors, thus serving as an ideal host for the study
of coreceptor activity [16]. Eagle’s minimum essential
medium (EMEM) (NISSUI Co., Inc. Tokyo, Japan) supple-
mented with 10% fetal bovine serum (FBS) was used to
maintain NP-2 cells and its derivatives. A panel of estab-
lished human cell lines was examined for the expression
of mRNA of CKR-L3- and CCR6-ORFs. T-cell lines, ATL-
1 K [17], C8166, Jurkat [18] and a B-cell line, Daudi [19]
were cultured in RPMI 1640 medium (NISSUI Co., Inc.)
containing 10% FBS. Hepatoma cell lines, huH1 [20]
and HepG2 [21] were cultured in Dulbecco’s modified
EMEM (DMEM) (NISSUI Co., Inc.) containing 10% FBS.
Human peripheral blood mononuclear cells (PBMC)
were isolated from the blood of a healthy donor using
Ficoll-Paque density gradient centrifugation (Pharmacia,
Uppsala, Sweden), then stimulated with phytohemagglu-
tinin (PHA) and cultured in RPMI 1640 medium supple-
mented with 20% FBS and 100 IU/ml of recombinant
interleukin-2 (IL-2). A human T-cell line, C8166 was
transduced with CCR5 to prepare C8166/CCR5 cells,
which were used for the preparation of viral stocks of
HIV and SIV strains [16]. The amphotropic packaging
cell line Phoenix-Ampho [22] was maintained in DMEM
containing 10% FBS.
Viruses
A panel of laboratory-adapted HIV-1 strains, GUN-1WT,
GUN-1V, GUN-4WT, GUN-4V, IIIB, BaL; and HIV-2
strains, CBL23, ROD, SBL6669, and SIV strains, mac251
and mndGB-1, were used to examine coreceptor activities
[13]. Primary isolates of HIV and SIV were obtained from
the National Institute for Biological Standard and Control
(NIBSC, London, UK). The characteristics of these isolates
with NIBSC-reference codes are as follows: HIV-1 strains,
MVP-5180 (Cameroon, subtype O, EVA167), 93BR020
(Brazil, subtype F, ARP179.25), 92US723 (USA, subtype B,
ARP1039.3), HAN2 (Germany, subtype B, EVA158). An
HIV-2 strain, MIR (Guinia Bissau, EVA171), and an SIV
primary isolate, smE660 (ARP1040), originated from a
sooty mangabey, were also included. A primary isolate
GUN11 was isolated from Gunma University Hospital
and used in this study.
Amplification of CKR-L3 open reading frame
The coding region DNA sequence of CKR-L3 was ob-
tained from the GenBank database (Accession number,
Z79784.1). Oligonucleotide primers were designed and
synthesized (Proligo K.K., Tokyo, Japan) covering its ORF
and to detect reverse-transcribed mRNA by PCR. Primers
sequences, orientations and positions in the respective
ORF were as follows: CKR-L3-F, 5′ ATGAATTTCAGCG
ATGTTTTCGACTCCAG 3′(sense: from the 1st to the
29th) and CKR-L3-R, 5′ TCACATAGTGAAGGACGAC
GCATTGTCG 3′(antisense: 1083rd-1110th). The native
CCR6-ORF (GenBank accession number, U60000.1) was
amplified accordingly. As controls, the mRNA expres-
sion of CD4 (M12807.1), CCR5 (U54994.1), CXCR4
(AY242129.1) and gleceraldehyde-3-phospahte dehydro-
genase (GAPDH, M17851.1) were also examined. Can-
didate ORFs amplified by RT-PCR were detected by
electrophoresis through 1% (w/v) agarose gel.
Cloning of CKR-L3 as coreceptor candidates
Amplified CKR-L3-ORF was cloned into a TA-cloning
plasmid, pGEM-T Easy (Promega, Madison, WI), and the
derivative plasmid was designated as pGEM-T Easy/CKR-
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L3. Sequencing of cloned DNA fragment was performed
by a 5500-sequencer (Hitachi, Tokyo, Japan) using fluores-
cent primers labeled with Texas Red. Restriction-digested
CKR-L3 ORF was re-cloned into an expression plasmid,
pMX-puro [23] and transfected into NP-2/CD4 cells to
produce and establish NP-2/CD4/CKR-L3 indicator cell
line as described earlier [16]. Similarly, NP-2/CD4/CCR6
cell line was used as running control, NP-2/CD4/CCR5
and NP-2/CD4/CXCR4 as positive controls and NP-2/
CD4 was used as a negative-control.
HIV and SIV infection assay
Receptor and coreceptor transduced NP-2/CD4/CKR-
L3, NP-2/CD4/CCR6, NP-2/CD4/CCR5, NP-2/CD4/
CXCR4 and NP-2/CD4 cells were seeded into 24-well
microtiter plates in a density of 50,000 cells/mL. After
overnight, medium was drained off with the addition of
viral inoculums to the seeded-cells. Following a six hour
incubation, the cells were washed three times with
EMEM containing 10% FBS to remove free virus, then
refilled with 500 μL fresh medium per well and cultured
at 37°C in a 5% CO2 incubator. In 3–5 day intervals, the
cell monolayers were disrupted with trypsin-EDTA
(0.25% trypsin, 1 mM EDTA), cell viability was checked
by 0.4% trypan blue staining solution, counted via he-
macytometer and re-seeded equal number of cells to
maintain uniform cell growth rate and maintained for
up to 8 weeks. The presence of viral antigens in the in-
fected cells was detected by indirect immunofluores-
cence assay (IFA) [24]. Retroviral infection was further
assured by detection of proviral DNA by PCR using the
genomic DNA of infected cells as templates [25]. Infec-
tion induced cell fusion was observed under light mi-
croscopy. Formation of syncytia was detected by Giemsa
staining (Muto Pure Chemicals, Tokyo, Japan). Subse-
quently, virus releases through different coreceptors
were quantified with measurement of reverse transcript-
ase (RT) activities in used culture supernatants [17].
Briefly, culture supernatants of virally infected cells were
precipitated with 30% polyethylene glycol and lysed with
standard disruption buffer containing 0.026% triton X-
100. Lysates were mixed with 50 μL of assay reaction
mixture consisting of 40 mM Tris HCl (pH 7.8), 4 mM di-
thiothreitol, 45 mM KCl, poly(rA), oligo(dT) (Pharmacia
Biotech, NJ), 15 μM [3H] (5 Ci/mmol) (Amersham
International, UK), and 10 mM MgCl2. The mixtures
were incubated for one hour at 37°C. Incorporation of
radioactivity into cold trichloroacetic acid–insoluble
fractions was assayed in a liquid scintillation counter
(Beckman Coulter LS 6500, CA). Ionization rate in counts
per minute (cpm) of culture supernatants was adjusted by
subtracting the background cpm. The assay was carried
out in duplicates.
Sequencing of viral DNA
The primer pair for proviral DNA of HIV-2MIR was
HIV2-F (forward 5′-ATGTGATAAGCACTATTGGGAT
GATA-3′) and HIV2-R (reverse 5′-CATGCTTGTTT
AGGTCTTGTATTGAT-3′), located between positions
of 7084-7109-nt and 7433-7458-nt, respectively, cover-
ing the C2-V3 env region (nucleotide positions of HIV-
2CRIK, DQ307022.1). For SIVsmE660, a proviral DNA
fragment of 773 nucleotides spanning the V1-V3 regions
of env gene was amplified as described earlier [26]. Upon
detection, the DNA bands were cloned into a TA-cloning
plasmid, pGEM-T Easy, and inserts were sequenced and
blasted in the NCBI nucleotide database (http://blast.ncbi.
nlm.nih.gov) to confirm the DNA integrity of the inocu-
lated viruses. Sequence alignments have been done using
the BioEdit program (version 7.2) for windows.
Statistical analysis
Mean percentages of the antigen-positive cells in two
independent infection assay and RT values in duplicate
samples were analyzed by paired t test using IBM SPSS
statistics data editor (version 17).
Nucleotide sequence accession numbers
The viral nucleotide sequences used in this study were
submitted to GenBank and were assigned accession
numbers: JN107567-69 for HIV-2MIR-CCR5, HIV-2MIR-
CKR-L3 and HIV-2MIR-CCR6, and the number JN107564-
66 for SIVsmE660-CCR5, SIVsmE660-CKR-L3, SIVsmE6
60-CCR6 clones, respectively.
Ethics statement
This study was approved by the ethical review commit-
tee of the Faculty of Medicine, Gunma University, Japan,
and standard written consent was obtained from the en-
rolled healthy blood donor.
Results
Detection of CKR-L3 and CCR6 expressions
The CKR-L3 ORF is similar to that of CCR6 except for
the absence of first five-amino acids in the NTR region.
The schematic diagram in Figure 1a indicates the point
of deletion at native CCR6 to represent CKR-L3. Expres-
sions of mRNA of both CKR-L3 and CCR6 were detected
by RT-PCR in PBMC, T cell lines, ATL1K and C8166 as
well as in hepatic cell lines, such as huH1 and HepG2
(Figure 1b). Similar to our findings, previous reports have
showed the expression of CKR-L3 in spleen, lymph nodes
and PBMC [15], whereas CCR6 was selectively expressed
on Th17 cells and regulatory T cells, memory T cells, B
cells and dendritic cells [27,28]. The 15-nucleotide size-
difference between the amplified ORFs of CKR-L3 and
CCR6 could not be distinguished fairly when they were
run through 1.5% agarose gel electrophoresis (Figure 1c).
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The major coreceptor, CCR5 was found to be expressed
on ATL-1 K and PBMC. The expression of CD4 was de-
tected on both the T cell lines and on PBMC.
Establishment of NP-2/CD4/coreceptor cells
Amplified ORFs of CKR-L3, CCR6 and CCR5 were trans-
duced one by one into NP-2/CD4 cells to produce NP-2/
CD4/coreceptor cells. The expression of the coreceptor
candidates were affirmed by detecting their specific mRNAs
in the transfected cell lines by RT-PCR. We ensured the ex-
pressions of respective candidates in NP-2/CD4/coreceptor
sub-lines by flow cytometry (FCM) following previously de-
scribed methods [29]. The mother cell, NP-2/CD4 did not
express any of the coreceptor candidates.
Coreceptor functions of CKR-L3 and CCR6
The coreceptor activities of CKR-L3 and CCR6 for HIV-
2MIR and SIVsmE660 primary isolates were noticed
when viral antigen-positive NP-2/CD4/CKR-L3 and NP-
2/CD4/CCR6 cells were detected by IFA (Figure 2a). We
have described the coreceptor-role of CCR6 in detail
previously [13]. The present report highlights the superior
coreceptor-role of CKR-L3 relative to its native counter-
part, CCR6. HIV-2MIR showed a good pace of replication
in NP-2/CD4/CKR-L3 cells and more than 80% cells be-
came antigen positive within 16 days after inoculation
(Figure 2b). To reach the same level of infection, CCR6-
transfected cells took one week more. In contrast, HIV-
2MIR attained the same level of infection in three to four
days in CCR5-transfected cells (Figure 2b). SIVsmE660
isolate was also highly infective via the CCR5 coreceptor:
more than 80% NP-2/CD4/CCR5 cells were antigen-
positive within one week after inoculation. This virus was
slow but progressive through the CKR-L3 coreceptor and
took six weeks to infect 80% of its cells. In contrast, CCR6
showed much weaker coreceptor activity than CKR-L3
Figure 1 Schematic structures of CKR-L3, CCR6 and their expression in different human cell lines. a) The amino acid sequence of NTR of
CCR6 isoform; shaded residues indicating region absent in CKR-L3 isoform. The arrow indicates the starting point for the translation for CKR-L3.
b) The expression of CKR-L3 in different human cells was detected by reverse transcriptase-PCR. The products shown in column 1 to 5 indicate
the mature full-length open reading frame (ORF) of CKR-L3 and right-most column shows molecular weight of marker. The cell lines expressed
CKR-L3-cDNA are specified separately in legend below. c) Comparative ORFs of CCR6 and CKR-L3 expressed in HepG2 cells.
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Figure 2 Immunofluorescence assay to detect the susceptibilities of NP-2/CD4/coreceptor cells and infection dynamics of HIV-2 and
SIV through different coreceptors. a) NP-2/CD4/coreceptor cells were seeded and next day inoculated with primary isolates, HIV-2MIR and
SIVsmE660. Cells were passaged in 3–4 day intervals and continued for four weeks for HIV-2 and eight weeks for SIV. Viral antigens in infected
cells were determined by IFA, for which cells were smeared onto glass slides in duplicate, dried, fixed with acetone and stained with pooled
human/monkey anti-HIV/SIV sera for HIV-2MIR- and SIVsmE660-antigen, respectively. Fluorescein isothiocyanate (FITC)-conjugated goat
anti-human and anti-monkey IgG were used as secondary antibodies. Specific days after inoculation on infected cells were shown accordingly.
b) Mean percentages of the antigen-positive cells in the two independent infection assay was calculated using IBM SPSS statistics data editor.
HIV-2MIR started progressive replication via CKR-L3 and CCR6; less than 10% cells became infected within the first week after inoculation and
gradually more than 80% cells became antigen-positive at day-16 and day-25 after inoculation, respectively. c) SIVsmE660 started slow infection
and took more adaptation time using CKR-L3 and CCR6 as coreceptors. The virus infected less than 10% of cells with in the first four weeks of
inoculation via either of the coreceptors, however, showed progressive infection to make more than 80% cells become antigen-positive at six
weeks via CKR-L3 and almost eight weeks via CCR6.
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taking 10 days more to produce similar levels of infection
(Figure 2c). However, infections via another major core-
ceptor, CXCR4, is not shown, but described in Table 1. A
second independent experiment had been done that re-
vealed similar outcomes.
Productive HIV and SIV infection in susceptible cells
in vitro or in vivo is often associated with the formation
of syncytia, which are multinucleated giant cells (MGC)
[30,31]. MGC in infected NP-2/CD4/CKR-L3 and NP-2/
CD4/CCR6 cells were quantified after fixation and staining
with Giemsa. Both HIV-2MIR and SIVsmE660 induced
syncytia formation using CKR-L3 and CCR6 as corecep-
tors (Figure 3a). However, syncytia formation through the
CKR-L3 coreceptor occurred more rapidly than with the
CCR6 coreceptor. Clusters were variable in sizes and con-
sisting of 10–25 nuclei per syncytium. Infection through
CCR5 frequently generated viral-induced MGC, while
coreceptor-negative NP-2/CD4 cells did not form any
cluster of nuclei (data not shown). Typically when cells
become infected by HIV and SIV, viral DNA provirus
forms by reverse transcription of genomic RNA into
double stranded DNA followed by subsequent integra-
tion into host DNA [32]. We further demonstrated in-
fection through the CKR-L3 and CCR6 coreceptors
through the detection of proviral DNA in infected cell
lines (Figure 3b). Retroviral cytopathic effects (CPE) in
cell-line-systems release a large amount of virus in to
cell-supernatant. The amount of produced viruses was
assessed by RT activities in spent culture media of viral
inoculated cells [33]. We observed sharp increases of
RT activities associated with CPE and cell ruptures. For
HIV-2MIR infection, RT release was measured at differ-
ent time points with a time dependent gradual increase
of antigen-positive cells as detected by IFA (Figure 3c).
The RT activities at the final time point of infection
cycles were 1.7 × 105, 1.6 × 105 and 1.2 × 105 cpm/mL
using CCR5, CKR-L3 and CCR6 coreceptors respect-
ively when 80-90% cells become antigen positive by IFA.
All the three cell lines generated four to six fold increases
of RT values during the last three days of respective infec-
tions (Figure 3c). However, the CKR-L3-transfected cell
line took a shorter time to release peak RT values com-
pared to that of CCR6. Contrast to HIV-2MIR, RT activ-
ities for SIVsmE660 infections were measured only at the
end points of each infection cycles. Culture fluids of in-
fected NP-2/CD4/CCR5 cells on day-seven, NP-2/CD4/
CKR-L3 cells on day-42 and NP-2/CD4/CCR6 cells on
day-52 were assayed for RT activities when CPE ascended
at the level of 80-90% cell infection (Figure 2c). The RT
releases using CCR5, CKR-L3 and CCR6 coreceptors for
SIVsmE660 were 2.3 × 106, 1.7 × 106 and 1.5 × 106 cpm/
mL, respectively. Very negligible RT activities (0.8-1.5 ×
103) were detected when the supernatants of virus-
infected NP-2/CD4 cell-cultures were measured.
Sequence analyses of the proviral DNAs
The sequences of HIV-2MIR and SIVsmE660 grown in
NP-2/CD4/CCR5, NP-2/CD4/CKR-L3 and NP-2/CD4/
CCR6 cells were validated by blasting with NCBI and
GenBank nucleotide databases. To analyze the genetic
divergence while propagating through different corecep-
tors, we aligned CCR5-clone to those of CKR-L3- and
CCR6-clones. For HIV-2MIR, the amplified C2-V3 re-
gion showed good integrity in the majority of the nu-
cleotide sequences among three clones. However, four
common nucleotide substitutions were found in the V3
region and three common changes were found in the
C2 region of the CKR-L3- and CCR6-clones compared
to the CCR5-clone sequence (Additional file 1). All of
the V3-substitutions were synonymous, revealing no amino
acid change. Unlike the V3 region, two non-synonymous
substitutions, namely lysine (K) to arginine (R) and trypto-
phan (W) to cysteine (C) were observed in the C2 region.
Table 1 Replication efficiency of laboratory-adapted
strains and primary isolates via different coreceptors in
NP-2/CD4/coreceptor cell line system
Virus Coreceptor in NP-2/CD4 cells:
CCR5 CXCR4 CKR-L3 CCR6 None
Laboratory isolates
HIV-1 IIIB - ++++a - - -
BaL ++++ - - - -
GUN1wt ++++ ++++ - - -
GUN1v ++ +++ - - -
GUN4wt +++ +++ - - -
GUN4v ++ +++ - - -
HIV-2 CBL23 ++ ++++ - - -
ROD ++ ++++ - - -
SBL6669 - ++++ - - -
SIV Mac251 ++++ - - - -
GBmnd1 ++++ ++ - - -
Primary isolates
HIV-1 MVP5180 ++++ ++++ - - -
93BR020 ++++ +++ - - -
92US723 ++++ - - - -
HAN2 ++++ ++++ + + -
GUN11 ++++ ++++ - - -
HIV-2 MIR ++++ ++++ +++ +++ -
SIV smE660 ++++ - +++ ++ -
aViral antigen positive cells were examined by IFA.
++++,70-90% of cells became antigen-positive within one week after infection;
+++,70-90% of cells became antigen-positive within two to four weeks of
infection; ++,70-90% of cells became antigen-positive within five to eight
weeks of infection; +,1-2% of cells become infected initially, however, did not
progress with time untill eight weeks of infection and -,<0.1% of cells became
antigen-positive within seven to eight weeks of infection.
































1   NP-2/CD4/CKR-L3 
2 NP-2/CD4/CCR6 
3 NP-2/CD4 






Figure 3 Retrovirus-induced syncytia formation, proviral DNA detection and RT assay. a) Syncytia formation of HIV/SIV as a sign of acute
infection was manifested by nuclear aggregation in multinucleated giant cells (MGC) detected by Giemsa staining. Both HIV-2MIR and SIVsmE660
induced syncytia formation in NP-2/CD4/CKR-L3 and NP-2/CD4/CCR6 cells. However, syncytia formation in the former cell line was shorter than
the latter for both viral variants. b) As evidence of retroviral DNA integration into the host cell genome, proviral DNA was detected by PCR using
the genomic DNA of the infected NP-2/CD4/CKR-L3 and NP-2/CD4/CCR6 cells as templates. c) Reverse transcriptase (RT) assay was done to detect
HIV-2MIR replication efficiency using CKR-L3 and CCR6 as coreceptors. Culture supernatants of infected cells were harvested at different time
points of infection-cycle. Mean cpm values of the duplicate samples were determined. CKR-L3 mediated increased and more rapid RT release
than that of CCR6.
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Another substitution of lysine to asparagine (N) was found
in the CCR6-clone, but not in the CKR-L3-using isolate
(Figure 4a).
The env gene for the V1-V3 region of CKR-L3- and
CCR6-variants of SIVsmE660 exhibited remarkable nucleo-
tide substitutions relative to that of the parental CCR5-
smE660: the levels were 1.4% (11/773) in smE660-CKR-L3
and 1.2% (9/773) in smE660-CCR6 clones. Of these four
substitutions were common for both clones (Additional file
2). Some of the nucleotide changes were synonymous.
However, non-synonymous substitutions of the CKR-L3-
variant were observed in the V1 region, with the change of
two threonines (T) into alanine (A) and valine (V) and one
alanine (A) into threonine (T). On the other hand, the
CCR6-variant demonstrated two changes, arginine (R) to
glycine (G) and vice-versa in the V1 region (Figure 4b). In
the V2 region, the CKR-L3-clone showed one amino
acid change, arginine (R) to lysine (K). The CCR-6 clone
remained unaltered. No amino acid substitution was
found in the V3 region of either the CKR-L3 or CCR6
clones. Interestingly, the C2 region showed two amino
acid changes in the CKR-L3 variant, glycine (G) to glu-
tamic acid (E) and arginine (R) to lysine (K). Likely, the
CCR6-variant also showed changes of glycine (G) to
glutamic acid (E) and arginine (R) to lysine (K) and in
addition one serine (S) to arginine (R) (Figure 4b).
Discussion
The majority of prior studies focused on coreceptor usage
by HIV and SIV have been concentrated on the two major
chemokine receptors, CCR5 and CXCR4. But many HIV
and SIV isolates have been reported to use alternative core-
ceptors in in vitro assays, belonging to CKRs and the or-
phan receptors such as CCR3 [34], CCR8 [35], FPRL1 [36],
GPR15 [37] and several others. There are many hurdles in
demonstrating the contribution of these alternative core-
ceptors to viral entry in vitro and their clinical relevance
in vivo. Recent in vivo studies have showed that SIV infects
CCR5-null cells, evidencing the physiologic relevance of al-
ternative coreceptors [12,38]. SIV strains were found to
competently infect cells utilizing multiple GPCRs, of both
human and sooty mangabey (SM)-origin as their entry
a)
b)
Figure 4 Sequence analysis of CKR-L3- and CCR6-variant of HIV-2MIR and SIVsmE660 isolates. The alignment of the C2-V3 amino acid
sequences of the HIV-2MIR for CKR-L3- and CCR6-variant has been made with the parental CCR5-variant. Similarly, alignment was made of the
V1-V3 amino acid sequences of the SIVsmE660 for the three variants. a) Each clone of CCR5-, CKR-L3- and CCR6-variant of HIV-2MIR has been
aligned. Dots indicate identity and letters represent substitutions in the adapted variants relative to the parental isolate. The positions of the
common amino acid changes are marked by ♦. The V3 domain is marked by dashes. b) Amino acid sequences of the three clones each from
CCR5-, CKR-L3- and CCR6-variant of SIVsmE660 covering the V1-V3 domains were aligned. The regions equivalent to V1, V2 and V3 are indicated
by dashes. Dots indicate the identity with the parental isolate; letters represent differences in the adapted variants. The positions of common
amino acid changes are marked by ▲.
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cofactor. However, CCR6 remains the latest member of the
coreceptor family that we have reported recently [13]. Like
many other GPCRs, the CCR6 has a natural isoform
named CKR-L3. Contrarily, in this study, we observed that
CKR-L3 exhibited greater coreceptor-activity than the pri-
mary CCR6 counterpart. Database (UniProtKB/Swis-Prot)
shows that CCR6 and CKR-L3 are encoded in the same
genome and expected to be translated from the first and
second methionines, respectively. Similarly, expression of
isoforms of the major coreceptor, CXCR4 were detected
earlier and their respective functions in chemokine sig-
naling and coreceptor activities have been described
previously [39,40]. However, there has been no reported
isoform of the major coreceptor CCR5 so far.
Initial HIV infection is considered to be facilitated via
CCR5 coreceptor activity [8] with evolution with CXCR4
during the later stage of infection [41]. However, a recent
data has demonstrated CXCR4-tropic viruses in early-
diagnosed infection, increasing the possibility of using
CXCR4 in early viral transmission [42]. So, together with
our findings, these data reflect the complexity of corecep-
tor shifting during HIV infection and the putative wider
spectrum of coreceptor activity during such infections.
In this study, we found that CKR-L3 facilitated infection
by three out of 18 HIV and SIV isolates tested. CCR6 also
facilitated infection by an equal number of viruses in our
previous study yielded. In contrast, both CCR5 and CXCR4
supported infection by the majority of isolates tested
(Table 1). These findings suggest CCR6 and CKR-L3 are
less-efficient coreceptors than the primary coreceptors,
CCR5 and CXCR4. However, these minor coreceptors
might be important entry pathways for viral infection
when major coreceptors are compromised or blocked as
described earlier [38].
CKR-L3 is a five amino acid deletion mutant from
NTR compared to CCR6 providing accelerated and bet-
ter infection efficiency in the NP-2/CD4 cell system. The
findings of our studies imply that the first five amino
acids in CCR6 are not essential for its coreceptor func-
tioning, which rather carry plausible negative roles in
coreceptor function. In a nutshell, the shorter coreceptor
version carries better coreceptor function. Similar find-
ings remain to that of CXCR4 isoforms as well [39,40].
On the other hand, among the deleted portion of CKR-
L3, there was no tyrosine residues, which were reported
to be part of the NTR of CCR5 considered vital for viral
entry [43]. Potential functional roles of tyrosines in the
CXCR4-NTR has been described in our previous reports,
where we showed a partial deletion of CXCR4-NTR con-
taining tyrosines abolishes its coreceptor function for many
dual tropic HIV and SIV viruses [44]. Therefore, the nat-
ural deletion of a small NTR-part without tyrosine from
CCR6 does not exert a deleterious coreceptor-function,
rather promotes CKR-L3. We assume that the increased
efficiency of CKR-L3 for viral entry is facilitated by the for-
mation of a protein structure that is more amenable to
interact with the retroviral envelope than that of the parent
CCR6 protein.
We observed that sequence comparison of the CKR-L3-
and CCR6-variants of HIV-2MIR to the CCR5-variant
showed no divergence in the V3 region. However, two-
and three-amino acid changes were found for CKR-L3-
and CCR6-variants in the C2 region, respectively. These
mutations in the C2 region may help the virus to adapt to
new coreceptor usage. Further sequencing analysis cover-
ing the full env region may provide more detailed informa-
tion of the possible mutations towards the evolution of
new quasispecies.
Similar to HIV-2MIR, the V3 region of the recovered
CKR-L3- and CCR6-variants of SIVsmE660 did not show
any amino acid changes compared to the CCR5-isolate.
These findings are congruent with a previous study that
described the region corresponding to the V3 of HIV-1
as highly conserved in SIV [45] and the genetic variation
of SIV as different from that of HIV-1 [46]. Our examin-
ation revealed the V1 and V2 regions of SIVsmE660 were
not conserved as like the V3 region. These findings are also
consistent with other reports describing sequence variation
mostly in the V1 region of SIV infections [47,48]. There-
fore, the V1 and V2 regions in the envelope glycoprotein
may carry the potentiality in determining receptor tropism.
Moreover, the CKR-L3-SIV variant showed more changes
in the V1 and V2 regions compared to its CCR6-variant.
These additional mutations may provide the recovered
SIVsmE660 with better adaptability, leading to accelerated
coreceptor activity for CKR-L3 as compared to CCR6.
More detailed sequence analyses throughout the env gene
or further full-length sequencing may provide more con-
clusive evidence for coreceptor-adaptation.
Conclusions
Our studies demonstrating the role of CKR-L3, an isoform
of CCR6, has extended our knowledge of viral pathogen-
esis. Further research will be needed to better understand
how these minor coreceptors may contribute to dissemin-
ating viral infection in vivo. Through validated experi-
ments, we have shown that the shorter isoform, CKR-L3
functioned as a better coreceptor than that of its parent
CCR6. The molecular basis behind the variation of the
coreceptor-strength between CKR-L3 and CCR6 requires
further detailed investigation.
Additional files
Additional file 1: The nucleotide sequences of the C2-V3 domains
of CCR5-, CKR-L3- and CCR6-clones of HIV-2MIR were aligned
together. Dots indicate the identity with the parental isolate; letters
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represent differences in the adapted variants. The V3 domain is indicated
by dashes.
Additional file 2: The nucleotide sequences of CCR5-, CKR-L3- and
CCR6-clones of SIVsmE660 covering V1-V3 regions were aligned.
Dots indicate the identity with the parental isolate; letters represent
differences in the adapted variants. The regions equivalent to the V1,
V2 and V3 of SIV are indicated by dashes.
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